de Wit R - Search Results

1

Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.

de Morrée E, van Soest R, Aghai A, de Ridder C, de Bruijn P, Ghobadi Moghaddam-Helmantel I, Burger H, Mathijssen R, Wiemer E, de Wit R, van Weerden W. de Morrée E, et al. Among authors: de bruijn p, de ridder c, de wit r. Prostate. 2016 Jul;76(10):927-36. doi: 10.1002/pros.23182. Epub 2016 Mar 21. Prostate. 2016. PMID: 26997363

2

Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.

de Wit R. de Wit R. Eur J Cancer. 2005 Mar;41(4):502-7. doi: 10.1016/j.ejca.2004.12.007. Epub 2005 Jan 26. Eur J Cancer. 2005. PMID: 15737553 Review.

3

[Effective chemotherapy for hormone-refractory prostate cancer: docetaxel-prednisone].

Batman E, de Wit R. Batman E, et al. Among authors: de wit r. Ned Tijdschr Geneeskd. 2005 Oct 29;149(44):2442-5. Ned Tijdschr Geneeskd. 2005. PMID: 16285357 Dutch.

4

Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.

Loos WJ, de Wit R, Freedman SJ, Van Dyck K, Gambale JJ, Li S, Murphy GM, van Noort C, de Bruijn P, Verweij J. Loos WJ, et al. Among authors: de bruijn p, de wit r. Cancer Chemother Pharmacol. 2007 Feb;59(3):407-12. doi: 10.1007/s00280-006-0359-6. Epub 2006 Oct 19. Cancer Chemother Pharmacol. 2007. PMID: 17051369

5

Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel.

Loos WJ, Zamboni WC, Engels FK, de Bruijn P, Lam MH, de Wit R, Verweij J, Wiemer EA. Loos WJ, et al. Among authors: de bruijn p, de wit r. J Pharm Biomed Anal. 2007 Oct 18;45(2):288-94. doi: 10.1016/j.jpba.2007.07.023. Epub 2007 Jul 26. J Pharm Biomed Anal. 2007. PMID: 17804188

6

Chemotherapy in hormone-refractory prostate cancer.

de Wit R. de Wit R. BJU Int. 2008 Mar;101 Suppl 2:11-5. doi: 10.1111/j.1464-410X.2007.07485.x. BJU Int. 2008. PMID: 18307687 Review.

7

When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?

Hamberg P, Verhagen PC, de Wit R. Hamberg P, et al. Among authors: de wit r. Eur J Cancer. 2008 Jun;44(9):1193-7. doi: 10.1016/j.ejca.2008.04.005. Epub 2008 Apr 28. Eur J Cancer. 2008. PMID: 18448326 Review.

8

The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.

Armstrong AJ, Halabi S, de Wit R, Tannock IF, Eisenberger M. Armstrong AJ, et al. Among authors: de wit r. Prostate Cancer Prostatic Dis. 2009;12(1):88-93. doi: 10.1038/pcan.2008.36. Epub 2008 Jun 24. Prostate Cancer Prostatic Dis. 2009. PMID: 18574490

9

Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer.

van Weerden WM, Bangma C, de Wit R. van Weerden WM, et al. Among authors: de wit r. Br J Cancer. 2009 Jan 13;100(1):13-8. doi: 10.1038/sj.bjc.6604822. Epub 2008 Dec 16. Br J Cancer. 2009. PMID: 19088719 Free PMC article. Review.

10

Chemotherapy in patients with castration-resistant prostate cancer.

Meulenbeld HJ, Hamberg P, de Wit R. Meulenbeld HJ, et al. Among authors: de wit r. Eur J Cancer. 2009 Sep;45 Suppl 1:161-71. doi: 10.1016/S0959-8049(09)70029-2. Eur J Cancer. 2009. PMID: 19775615 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

470 results

Search Page

Filters